Organon & Co. (NYSE:OGN) Reaches New 1-Year High – Should You Buy?

Organon & Co. (NYSE:OGN)’s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.89 and last traded at $13.8850, with a volume of 1,337,922 shares. The stock had previously closed at $13.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Organon & Co. has an average rating of “Reduce” and a consensus price target of $12.00.

Organon & Co. Price Performance

The company has a current ratio of 2.02, a quick ratio of 1.51 and a debt-to-equity ratio of 7.11. The company has a market capitalization of $3.65 billion, a P/E ratio of 18.28, a P/E/G ratio of 1.28 and a beta of 1.53. The business’s fifty day moving average price is $13.76 and its 200-day moving average price is $11.66.

Organon & Co. (NYSE:OGN) last released its earnings results on Friday, October 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, sell-side analysts predict that Organon & Co. will post 3.24 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, November 9th. Organon & Co.’s dividend payout ratio is presently 10.53%.

Hedge Funds Weigh In On Organon & Co.

Large investors have recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new stake in shares of Organon & Co. in the 3rd quarter valued at $919,000. Voya Investment Management LLC raised its position in Organon & Co. by 1.5% in the 3rd quarter. Voya Investment Management LLC now owns 81,254 shares of the company’s stock worth $1,113,000 after purchasing an additional 1,232 shares during the period. HighTower Advisors LLC raised its position in Organon & Co. by 3.9% in the 3rd quarter. HighTower Advisors LLC now owns 48,346 shares of the company’s stock worth $662,000 after purchasing an additional 1,797 shares during the period. Alberta Investment Management Corp lifted its stake in Organon & Co. by 22.2% in the third quarter. Alberta Investment Management Corp now owns 550,000 shares of the company’s stock worth $7,535,000 after purchasing an additional 100,000 shares during the last quarter. Finally, First Trust Capital Management L.P. lifted its stake in Organon & Co. by 2.8% in the third quarter. First Trust Capital Management L.P. now owns 402,040 shares of the company’s stock worth $5,508,000 after purchasing an additional 11,101 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.